NGNE Stock Overview
A biotechnology company, develops genetic medicines for rare neurological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Neurogene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.06 |
| 52 Week High | US$74.49 |
| 52 Week Low | US$14.42 |
| Beta | 0 |
| 1 Month Change | -34.44% |
| 3 Month Change | -67.21% |
| 1 Year Change | -52.49% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -0.26% |
Recent News & Updates
Shareholder Returns
| NGNE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.3% | 3.6% | 1.8% |
| 1Y | -52.5% | -3.7% | 24.9% |
Return vs Industry: NGNE underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: NGNE underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| NGNE volatility | |
|---|---|
| NGNE Average Weekly Movement | 26.5% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NGNE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NGNE's weekly volatility has increased from 16% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 91 | Rachel McMinn | www.neurogene.com |
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC.
Neurogene Inc. Fundamentals Summary
| NGNE fundamental statistics | |
|---|---|
| Market cap | US$223.71m |
| Earnings (TTM) | -US$3.28m |
| Revenue (TTM) | US$925.00k |
241.9x
P/S Ratio-68.3x
P/E RatioIs NGNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGNE income statement (TTM) | |
|---|---|
| Revenue | US$925.00k |
| Cost of Revenue | US$57.65m |
| Gross Profit | -US$56.73m |
| Other Expenses | -US$53.45m |
| Earnings | -US$3.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | -6,132.86% |
| Net Profit Margin | -354.16% |
| Debt/Equity Ratio | 0% |
How did NGNE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/26 09:38 |
| End of Day Share Price | 2025/01/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neurogene Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Keith Tapper | BMO Capital Markets Equity Research |
| Mitchell Kapoor | H.C. Wainwright & Co. |